Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
138.15
-1.26 (-0.90%)
At close: Nov 7, 2025, 4:00 PM EST
138.50
+0.35 (0.25%)
After-hours: Nov 7, 2025, 6:56 PM EST
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 20 analysts that cover Axsome Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $176, which forecasts a 27.40% increase in the stock price over the next year. The lowest target is $143 and the highest is $205.
Price Target: $176 (+27.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 8 | 9 |
| Buy | 9 | 10 | 10 | 11 | 11 | 11 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 18 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $200 → $202 | Buy | Maintains | $200 → $202 | +46.22% | Nov 6, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $194 → $196 | Buy | Maintains | $194 → $196 | +41.87% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $180 → $185 | Strong Buy | Maintains | $180 → $185 | +33.91% | Nov 4, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $189 → $198 | Buy | Maintains | $189 → $198 | +43.32% | Nov 4, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $163 → $157 | Buy | Maintains | $163 → $157 | +13.64% | Nov 4, 2025 |
Financial Forecast
Revenue This Year
631.22M
from 385.69M
Increased by 63.66%
Revenue Next Year
974.98M
from 631.22M
Increased by 54.46%
EPS This Year
-3.68
from -5.99
EPS Next Year
0.83
from -3.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 673.0M | 1.1B | |||
| Avg | 631.2M | 975.0M | |||
| Low | 589.1M | 762.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 74.5% | 81.2% | |||
| Avg | 63.7% | 54.5% | |||
| Low | 52.7% | 20.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.94 | 4.20 | |||
| Avg | -3.68 | 0.83 | |||
| Low | -4.17 | -2.91 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.